Terminology Service for NFDI4Health
JSON

Lapatinib

Go to external page http://purl.obolibrary.org/obo/NCIT_C26653

A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. [ ]

Term info

Label

Lapatinib

Synonyms
  • GSK572016
  • GW 2016
  • GW2016
  • GW572016
  • LAPATINIB
  • Lapatinib
  • lapatinib
Subsets

NCIT_C128784, NCIT_C63923, NCIT_C157711, NCIT_C157712

ALT DEFINITION

A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.

CAS Registry

231277-92-2

CHEBI ID

CHEBI:49603

Chemical Formula

C29H26ClFN4O4S

FDA UNII Code

0VUA21238F

Has Salt Form

http://purl.obolibrary.org/obo/NCIT_C66878

Has Target

http://purl.obolibrary.org/obo/NCIT_C17068, http://purl.obolibrary.org/obo/NCIT_C17319, http://purl.obolibrary.org/obo/NCIT_C41625

NSC Code

727989

Preferred Name

Lapatinib

Semantic Type

Pharmacologic Substance, Organic Chemical

UMLS CUI

C1506770

code

C26653